Preclinical studies have shown that the genetic and pharmacological abrogation of DNA-PK signaling, the latter using the DNA-PK inhibitors KU-0060648 and NU7441, leads to the selective killing of ATM-defective CLL cells [72,73]. The gene discussed is ATM; the disease is B-cell chronic lymphocytic leukemia.